Showing 1–5 of 5 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Morrish Okello-Obol, Ivaan Pitua, James Nelson Okema, Doris Ekwem, Felix Bongomin, et al.
…f drug-resistant TB (DR-TB) and its strong association with HIV. Bedaquiline (BDQ), approved by the WHO in 2013, offers a promising treatment for DR-TB, including multidrug-resistant TB (MDR-TB) and extensively DR-TB (XDR-TB). However, BDQ has been associated with QT interval pro…
Youssra Metarfi, Wissal Chellal, Zineb Ben Khadda, Hasnae Hoummani, Bouchra Amara, et al.
…n, and patients with MDR- and XDR-TB, as well as those with HIV co-infection. The studies examine a range of anti-TB drugs, from first-line treatments like isoniazid and rifampicin to second-line options such as bedaquiline and linezolid. Various sampling methods were employed, i…
Alberto Matteelli, Sofia Lovatti, Benedetta Rossi, Luca Rossi
…afe, demonstrates good efficacy, and does not interact with HIV therapies. Despite these promising results, pre-extensively drug-resistance (XDR)-TB (MDR-TB with documented resistance to quinolones) remains an emerging concern. Two ongoing trials will address this challenge: the …
Salman Daneshi, Esmaeil Barkhori Mehni, Mohammad Kamali, Eshagh Barfar, Fatemeh Bagher Barahouei, et al.
… to new cases. Comorbidities such as diabetes (OR: 2.3) and HIV (OR: 3.1), along with male sex and older age, were significant contributing factors-particularly in XDR-TB cases. Despite the rising trend in drug resistance, diagnostic and laboratory limitations remain major challe…
Jenifer A Otieno, Lisa Malesi Were, Vittoria Lutje, Katie Scandrett, Yemisi Takwoingi, et al.
…nerable populations such as children and people living with HIV, to inform health equity considerations. **SEARCH METHODS:** We searched Cochrane CENTRAL, MEDLINE, Embase, five other electronic bibliographic databases, and two trial registries, from 1900 up to 21 January 2025. W…